-
1 Comment
Wooridul Pharmaceutical Limited is currently in a long term uptrend where the price is trading 14.1% above its 200 day moving average.
From a valuation standpoint, the stock is 83.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Wooridul Pharmaceutical Limited's total revenue rose by 9.8% to $26B since the same quarter in the previous year.
Its net income has increased by 967.6% to $6B since the same quarter in the previous year.
Finally, its free cash flow grew by 87.5% to $-282M since the same quarter in the previous year.
Based on the above factors, Wooridul Pharmaceutical Limited gets an overall score of 5/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ISIN | KR7004720009 |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Beta | 0.63 |
| Market Cap | 74B |
| Dividend Yield | None |
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 004720.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
